We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.51B
AUM Growth
-$254M
Cap. Flow
-$15.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
28.7%
Holding
145
New
11
Increased
46
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$25.7M
2
AMGN icon
Amgen
AMGN
+$24.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.6M
4
QURE icon
uniQure
QURE
+$11.2M
5
CNC icon
Centene
CNC
+$11.2M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$77.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$47.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$31.8M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$23.8M
5
A icon
Agilent Technologies
A
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 86.82%
2 Consumer Staples 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$382B
$128M 5.12%
591,000
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.2B
$111M 4.43%
1,232,500
+209,500
+20% +$19.6M
WCG
3
DELISTED
Wellcare Health Plans, Inc.
WCG
$83.1M 3.31%
320,500
– –
ISRG icon
4
Intuitive Surgical
ISRG
$127B
$82.3M 3.28%
457,500
– –
AMRN
5
Amarin Corp
AMRN
$297M
$70.5M 2.81%
232,500
+6,250
+3% +$2.18M
HCA icon
6
HCA Healthcare
HCA
$90.6B
$56.3M 2.24%
467,500
+12,500
+3% +$1.62M
EHC icon
7
Encompass Health
EHC
$11.3B
$51.6M 2.06%
1,024,455
+12,570
+1% +$632K
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$49M 1.95%
505,371
– –
TFX icon
9
Teleflex
TFX
$5.96B
$44.2M 1.76%
130,000
– –
PCRX icon
10
Pacira BioSciences
PCRX
$1.04B
$43.8M 1.74%
1,150,000
-100,000
-8% -$3.99M
PODD icon
11
Insulet
PODD
$11.8B
$43M 1.71%
260,500
+16,000
+7% +$2.25M
IRTC icon
12
iRhythm Holdings
IRTC
$4.02B
$41.1M 1.64%
555,000
+55,385
+11% +$4.29M
EW icon
13
Edwards Lifesciences
EW
$49.4B
$40.4M 1.61%
550,500
– –
ACHC icon
14
Acadia Healthcare
ACHC
$2.52B
$40.1M 1.6%
1,290,000
+235,000
+22% +$7.16M
MDCO
15
DELISTED
Medicines Co
MDCO
$40M 1.59%
800,000
– –
ABBV icon
16
AbbVie
ABBV
$465B
$39.8M 1.58%
525,000
+375,000
+250% +$25.7M
BSX icon
17
Boston Scientific
BSX
$68.4B
$39.5M 1.57%
970,000
– –
EXAS
18
DELISTED
Exact Sciences
EXAS
$39M 1.55%
431,750
+34,750
+9% +$3.96M
SYK icon
19
Stryker
SYK
$135B
$38.7M 1.54%
179,000
– –
CHRS icon
20
Coherus Oncology
CHRS
$217M
$38.1M 1.52%
1,880,000
– –
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$123B
$34.4M 1.37%
203,000
– –
BAX icon
22
Baxter International
BAX
$12.8B
$33.7M 1.34%
385,000
+84,300
+28% +$7.2M
RDUS
23
DELISTED
Radius Health, Inc.
RDUS
$33.5M 1.33%
1,300,000
+50,000
+4% +$1.23M
CI icon
24
Cigna
CI
$78.4B
$32.9M 1.31%
216,900
+34,600
+19% +$5.63M
IDXX icon
25
Idexx Laboratories
IDXX
$44.9B
$32.7M 1.3%
120,200
– –
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Rock Springs Capital Management held 145 positions worth $2.51B, down 9.2% from $2.76B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2019 filing shows 11 new, 46 increased, 10 reduced and 7 closed positions. Its largest new stake was Amgen: 126,000 shares worth $24.4M. The largest sale was GW Pharmaceuticals Plc American Depositary Shares, an estimated $77.4M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier, followed by Consumer Staples.

  • Rock Springs Capital Management's largest Q3 2019 buy was Amgen: 126,000 shares worth $24.4M.
  • Rock Springs Capital Management added most to AbbVie in Q3 2019, an estimated $25.7M increase.
  • Rock Springs Capital Management's biggest Q3 2019 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $77.4M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q3 2019, selling an estimated $47.6M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.51B portfolio in Q3 2019.
  • Rock Springs Capital Management opened 11 new positions and closed 7 in Q3 2019.
  • Rock Springs Capital Management's portfolio value fell 9.2% quarter-over-quarter to $2.51B.

Based on Rock Springs Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.